JPS5846015A - Medicinal preparation - Google Patents
Medicinal preparationInfo
- Publication number
- JPS5846015A JPS5846015A JP14362881A JP14362881A JPS5846015A JP S5846015 A JPS5846015 A JP S5846015A JP 14362881 A JP14362881 A JP 14362881A JP 14362881 A JP14362881 A JP 14362881A JP S5846015 A JPS5846015 A JP S5846015A
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- sensitive adhesive
- base material
- adhesive layer
- flexible base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【発明の詳細な説明】
本発明はりatt−−ゼを含有する新規な医薬製剤に関
するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to novel pharmaceutical formulations containing att-ase.
ウロキナーゼは、分子量が約33000又は54000
の壷白諺素で、血栓溶解剤として広く、使用されており
、適応症としては末梢動脈血栓症、肺栓塞症、冠動脈閉
塞症、網膜静脈血栓症などが挙げられている。Urokinase has a molecular weight of approximately 33,000 or 54,000
It is widely used as a thrombolytic agent, and indications include peripheral artery thrombosis, pulmonary embolism, coronary artery occlusion, and retinal vein thrombosis.
これらの治療のために、クロキt−4は静脈注射されて
使用されているが、局所へ達する量が少ないために、大
量投与する必要があった。そのために副作用が起生ずる
という間嘔があった。For these treatments, Kuroki T-4 is used by intravenous injection, but since the amount that reaches the local area is small, it is necessary to administer large amounts. This caused side effects such as nausea.
そこで近年ウロキナーゼを含有する軟膏タイプの外用剤
を皮膚i1Km!布して、ウロキナーゼを経皮吸収させ
、局所皮膚疾患や血症症を治療することが提案されてい
、るが、投薬量を定量化することができないという重大
な欠点と、軟膏を塗布した部分に覆いが必要であるとい
りた煩雑さがある。Therefore, in recent years, an ointment-type external preparation containing urokinase has been introduced for skin i1Km! It has been proposed that urokinase can be absorbed transdermally by applying ointment to the skin to treat local skin diseases and hemophilia, but the major disadvantage is that the dosage cannot be quantified and the area to which the ointment is applied There are complications such as the need for a cover.
本発明は定量の投薬量で、しかも簡便な操作で経皮吸収
するようにできる、クロキナーイ會有テープ製剤を提供
するもので、その要旨とするところは、可撓性部材0表
面に、クロキナーゼを含有する感圧接着剤層が形成され
ていることである。The present invention provides a tape preparation containing crokinase, which can be absorbed transdermally with a fixed dosage and by a simple operation. A pressure sensitive adhesive layer containing .
本発明に用いられる感圧接着剤としては、(メタ)アク
リル酸ブチル、(メタ)アクリル駿2−エチルへキシル
の如き(メタ)アクリル酸エステルと、該エステル類と
共重合可能な(メタ)アクヅル酸、アクツル酸ヒドロキ
Vエチル、(メタ)アクツル酸メトオキシエチルの如き
官能性モノマー及び/又は酢酸ビニル、プロピオン酸ビ
ニルの如きビニル七ツマ−との共重合物、ボッアクリル
酸塩O如き水溶性アクリル系ポリマーに、グリセリンの
如きアルコール類、ボッイソシアネートの如き架橋成分
及び水を配合した架橋含水ゲル、その他ポリイソブチレ
ンゴム、Vツコーンゴム、スチレン−イソプレン−スチ
レンブロック共重合体ゴムを主成分とする接着性物質な
どが用いられる。The pressure-sensitive adhesive used in the present invention includes (meth)acrylic esters such as butyl (meth)acrylate and 2-ethylhexyl (meth)acrylate, and (meth)acrylates copolymerizable with the esters. Copolymers with functional monomers such as acturic acid, hydroxyethyl acturate, methoxyethyl (meth)acturate and/or vinyl heptadurates such as vinyl acetate and vinyl propionate, water-soluble acrylates such as octyl acrylate O A crosslinked hydrogel made by blending a polyacrylic polymer with an alcohol such as glycerin, a crosslinking component such as boisocyanate, and water, and other materials whose main components are polyisobutylene rubber, V-tcone rubber, and styrene-isoprene-styrene block copolymer rubber. An adhesive substance or the like is used.
これらの共重合物、ゲル及び接着性物質からなる感圧接
着剤には、ウロキナーゼが配合され、可撓性部材上に層
状(厚さ約10〜300声惰が好ましい)に形成される
。A pressure-sensitive adhesive made of these copolymers, a gel, and an adhesive substance is blended with urokinase, and is formed in a layer (preferably about 10 to 300 layers thick) on a flexible member.
層中のクロキナーゼの量は、概して200〜50000
1U/all(国際単位/―)の範囲とするのが好まし
く、200IU/?曾以下では充分な薬理効果が得られ
ず、50000 I U/a++F以上では経痔的でな
い。The amount of crokinase in the layer is generally 200-50,000
It is preferably in the range of 1U/all (international unit/-), and 200IU/? If it is less than 50,000 IU/a++F, no sufficient pharmacological effect will be obtained, and if it is more than 50,000 IU/a++F, it will not cause hemorrhoids.
クロキナーゼと前記感圧接着剤との配合系には、角質の
保水機能、角質の膨化又は軟化機能、角質のぬれ性向上
機能及び毛孔開孔機能などのクロキナーゼの経皮吸収促
進に寄与する機能を有する助剤を適量(概して0.5〜
sO重量%)配合することができる。The combination system of crokinase and the pressure-sensitive adhesive has functions that contribute to the promotion of transdermal absorption of crokinase, such as the function of retaining water in the stratum corneum, the function of swelling or softening the stratum corneum, the function of improving wettability of the stratum corneum, and the function of opening pores. Appropriate amount of functional auxiliary agent (generally 0.5~
sO weight %) can be blended.
該助剤としては、ジメチルスルホキナイドに代表される
スルホキサイド類、ジメテルアセタアミドに代表される
アミド類、その他オリーブ油、ナデデル酸、シイツブσ
ビルアジペート、夛すテル酸メチル、蛋白分解鱈素、ア
ルコール類などが挙げられるが、これKfi定されるも
のではない。Examples of the auxiliary agents include sulfoxides such as dimethylsulfoquinide, amides such as dimethylacetamide, and others such as olive oil, nadederic acid, and sulfuric acid.
Examples include viradipate, methyl tellate, proteolytic cod, alcohols, etc., but the Kfi of these is not determined.
このようにクロキナーゼが配合された感圧接着剤は、必
要に応じて前記の助剤類及び増粘剤、充填剤、粘着付与
性樹脂などの公知の配合剤が添加され、ポリエステル、
ポックレタン、ポリエチレン、ポリ塩化ビニルなどのプ
ラスチックフィルム又は不織布、発泡フィルムなど、或
いはこれらの積層フィルムなどからなる可撓性部材(厚
さ約10〜300声S)の表面く形成され、医薬製剤と
される。The pressure-sensitive adhesive containing crokinase is prepared by adding the above-mentioned auxiliaries and known compounding agents such as thickeners, fillers, and tackifying resins as necessary, and adding polyester,
It is formed on the surface of a flexible member (thickness approximately 10 to 300 mm) made of plastic film such as Pockrethane, polyethylene, or polyvinyl chloride, nonwoven fabric, foamed film, etc., or a laminated film of these, and is used as a pharmaceutical preparation. Ru.
本発明の医薬製剤は、定量の投薬量で、疾患部K11l
!に適用できるという特徴を有するものであるが、例え
ば湿疹、紅斑、そンドール症、血管炎、血行障害、熱傷
、亀□傷、凍傷、凍傷、水澄症、内皮症、皮膚硬化症な
どの治療、或いは制ガン剤、ステロイド剤などの作用増
強にも使用できる。The pharmaceutical formulation of the invention, in fixed dosages, can be applied to diseased areas K11l
! It has the characteristic that it can be applied to, for example, eczema, erythema, chondorosis, vasculitis, blood circulation disorders, burns, tortoise wounds, frostbite, frostbite, water clearness, endotheliosis, skin sclerosis, etc. Alternatively, it can be used to enhance the action of anticancer drugs, steroid drugs, etc.
以下本発明の実施例を示す。Examples of the present invention will be shown below.
実施例1
アクリル酸2−エチルへキシル:アクリル酸:過酸化ベ
ンゾイル(BPO):酢酸工fstwz 95:5:0
.5:25(重量比)を常法により重合して、共重合物
溶液を得る。゛
該溶液の固型分100重量部に対して、助剤としてのオ
リーブ油5重量部及びナリテル酸2重量部を配合し、ざ
らFC10p需の糊厚において、200001U/IP
の量となるようにクロキナーゼを配合して混合物を作り
、これを酸化処理したポリエチレンフィルムの処理面に
%乾燥後の厚みが70声富となるように塗布乾燥して、
医薬製剤を得た。Example 1 2-ethylhexyl acrylate: acrylic acid: benzoyl peroxide (BPO): acetic acid fstwz 95:5:0
.. A copolymer solution of 5:25 (weight ratio) is obtained by polymerizing in a conventional manner.゛To 100 parts by weight of the solid content of the solution, 5 parts by weight of olive oil and 2 parts by weight of naliteric acid as auxiliaries were blended, and at a paste thickness of 10p of Zara FC, 200001U/IP
A mixture was made by blending crokinase in an amount of
A pharmaceutical formulation was obtained.
実施例2
ポリアクリル酸tトリ1クム(平均重合度約2万):ブ
ツセラン二本:トッグリνジルイソレアヌレート−6:
15:69:1 (重量比)を加熱混合してゲル基材を
得る。Example 2 Tricum polyacrylate (average degree of polymerization of about 20,000): 2 butuserans: Toggly ν diisoleanurate-6:
A gel base material is obtained by heating and mixing 15:69:1 (weight ratio).
この基材に助剤としてのシイツブσビルアジベ′シを5
重量部配合し、さらにゲル厚70p*において、100
OOIU/alFの量となるようにクロキナーゼを配合
して、混合ゲル基材を作り、これをポリフレタンラミネ
ートレーヨン不織布の表面K。Add 55% of Shiitsubu σ Biru Ajibe'shi as an auxiliary agent to this base material.
Parts by weight are blended, and at a gel thickness of 70p*, 100
Clokinase was blended in an amount of OOIU/alF to make a mixed gel base material, and this was applied to the surface of polyurethane laminated rayon nonwoven fabric.
ゲル化後の厚みが70声需となるように塗布してゲル化
させ、医薬製剤を得た。A pharmaceutical formulation was obtained by applying and gelling the mixture so that the thickness after gelling would be 70 mm.
実施例3
アクリル酸エトキシエテル:アクリル酸2−エテルヘキ
レA/ニアクリル酸:BPO:酢酸エチル諺20ニア7
:3:0.5:2B (重量比)を常法により重合して
、共1合物溶液を得る。Example 3 Ethoxyethyl acrylate: 2-ethyl acrylic acid A/Niacrylic acid: BPO: Ethyl acetate Proverb 20 Niac 7
:3:0.5:2B (weight ratio) is polymerized by a conventional method to obtain a co-1 compound solution.
該溶液の一型分100重量部に対して、助剤としてOジ
メチルスルホキナイドを3重量部配合し、さらに70声
層の糊厚において500IU/−の量となるようにクロ
キナーゼを配合して混合物を作り、これをポリフレタン
発泡フィルム(厚さ1sIl)の表面に乾燥後の厚みが
70声譚となるように塗布乾燥して、医薬製剤を得た。To 100 parts by weight of the solution, 3 parts by weight of O-dimethylsulfoquinide was added as an auxiliary agent, and crokinase was added in an amount of 500 IU/- in the glue thickness of 70 vocal layers. A mixture was prepared, and this was applied onto the surface of a polyurethane foam film (thickness: 1 sIl) so that the thickness after drying was 70 mm, and dried to obtain a pharmaceutical preparation.
第1表は実施例1〜3の測定評価結果を示すものである
。第、1表中の参考例は、クロキナーゼ2000011
7(IP)、ステアリン酸25P、セタノールlj’、
ラノリン1ノ、グリセリン5P、トリエタノールア
ミン3ノ及び精製水64JPとからなるゲル状軟膏の評
価結果を示している。なお第1表中の接着力は、サンプ
ル(12IJ幅)をベークライト板に貼着し、180度
で引き剥がして求めた(測定条件20℃×65%、引張
速度300fi/zin)。Table 1 shows the measurement and evaluation results of Examples 1 to 3. The reference example in Table 1 is Clokinase 2000011
7 (IP), stearic acid 25P, cetanol lj',
It shows the evaluation results of a gel ointment consisting of 1 part of lanolin, 5 parts of glycerin, 3 parts of triethanolamine, and 64 parts of purified water. The adhesive strength in Table 1 was determined by attaching a sample (12 IJ width) to a Bakelite plate and peeling it off at 180 degrees (measurement conditions: 20° C. x 65%, tensile speed: 300 fi/zin).
また薬理効果は10人のパネラ−の熱傷部分にサンプル
を貼り付けて評価したもので、分子は効果の得られたパ
ネラ−の数を示している。The pharmacological effects were evaluated by applying the sample to the burn area of 10 panelists, and the numerator indicates the number of panelists in whom the effect was obtained.
第 l 表
上記実施例からも明らかな如く、本発明の医薬製側は効
果面においては軟膏と同等か或いはそれ以上(殊に実施
例2のゲルを用いたもの)の値を示し、しかも投薬量が
正確で、施用前後の処置が簡便であるという事実が顕著
である。Table 1 As is clear from the above examples, the pharmaceutical product of the present invention has an effect equal to or greater than that of the ointment (particularly when using the gel of Example 2), and moreover, Remarkable is the fact that the dosage is accurate and the treatment before and after application is simple.
特許出願人 日東電気工業株式会社 代表者土方三部patent applicant Nitto Electric Industry Co., Ltd. Representative Sanbe Hijikata
Claims (1)
接着剤層が形成されている医薬製剤。 ■ウロキナーゼの含有量が200〜5oooo tυ/
−である特許請求の範囲第1項記載の医薬製剤。[Scope of Claims] 1) A pharmaceutical preparation in which a pressure-sensitive adhesive layer containing urokinase is formed on the surface of a flexible member. ■Urokinase content is 200-5oooo tυ/
- The pharmaceutical formulation according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14362881A JPS5846015A (en) | 1981-09-10 | 1981-09-10 | Medicinal preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14362881A JPS5846015A (en) | 1981-09-10 | 1981-09-10 | Medicinal preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS5846015A true JPS5846015A (en) | 1983-03-17 |
Family
ID=15343169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14362881A Pending JPS5846015A (en) | 1981-09-10 | 1981-09-10 | Medicinal preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5846015A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60214362A (en) * | 1984-04-11 | 1985-10-26 | Ricoh Co Ltd | Electrostatic recording body |
JPS61100756A (en) * | 1984-10-23 | 1986-05-19 | Daicel Chem Ind Ltd | Electrostatic recording body |
US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
WO1999033458A1 (en) * | 1997-12-25 | 1999-07-08 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition for percutaneous administration |
US7588784B2 (en) * | 2007-10-05 | 2009-09-15 | Attila Mady | Use of onion extracts to prevent and treat acute and chronic cardiac and vascular complications and their sequelae, as well as to resolve hematomas |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
JPS5276416A (en) * | 1975-12-22 | 1977-06-27 | Nikkiso Co Ltd | Preparation of medical material with antiaggulutinating activity |
JPS5585516A (en) * | 1978-11-27 | 1980-06-27 | Japan Atom Energy Res Inst | Method of preparing polymer composition containing carcinostatic substance |
-
1981
- 1981-09-10 JP JP14362881A patent/JPS5846015A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
JPS5276416A (en) * | 1975-12-22 | 1977-06-27 | Nikkiso Co Ltd | Preparation of medical material with antiaggulutinating activity |
JPS5585516A (en) * | 1978-11-27 | 1980-06-27 | Japan Atom Energy Res Inst | Method of preparing polymer composition containing carcinostatic substance |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60214362A (en) * | 1984-04-11 | 1985-10-26 | Ricoh Co Ltd | Electrostatic recording body |
JPS61100756A (en) * | 1984-10-23 | 1986-05-19 | Daicel Chem Ind Ltd | Electrostatic recording body |
US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
US5817331A (en) * | 1990-11-28 | 1998-10-06 | Sano Corporation | Transdermal administration of azapirones |
US5837280A (en) * | 1990-11-28 | 1998-11-17 | Sano Corporation | Transdermal administration of azapirones |
WO1999033458A1 (en) * | 1997-12-25 | 1999-07-08 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition for percutaneous administration |
US7588784B2 (en) * | 2007-10-05 | 2009-09-15 | Attila Mady | Use of onion extracts to prevent and treat acute and chronic cardiac and vascular complications and their sequelae, as well as to resolve hematomas |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS61280426A (en) | Anti-inflammatory and analgesic application agent | |
JPH0363223A (en) | Estradiol compound and its local application | |
US4954343A (en) | Dermal pharmaceutical preparations | |
EP0450986B1 (en) | A percutaneous-administration-type pharmaceutical preparation of nitroglycerin | |
JPH04266818A (en) | Tacky agent for medical application | |
JPS5846015A (en) | Medicinal preparation | |
JPS632533B2 (en) | ||
JP3689494B2 (en) | Base for preparations for transdermal absorption | |
JPS6019890B2 (en) | Anti-inflammatory analgesic patch | |
JPH0339488B2 (en) | ||
JPH06145050A (en) | Production of patch | |
JPS597689B2 (en) | pharmaceutical formulations | |
JPS5928534B2 (en) | patch | |
JPS596286B2 (en) | tape formulation | |
JPS607966B2 (en) | patch | |
JP3232810B2 (en) | Film-forming external preparation | |
JPH0543457A (en) | Percutaneously absorbable preparation | |
JPS63270060A (en) | Antibacterial adhesive member | |
JPS62112557A (en) | Patch agent for external application | |
JPS6124366B2 (en) | ||
JP3448780B2 (en) | Nitroglycerin patch | |
JPS61221121A (en) | Tape preparation | |
JPS5928533B2 (en) | patch | |
JPS6126967B2 (en) | ||
JPH034524B2 (en) |